{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "\nHAQ\n",
      "pain",
      "patient-reported outcomes",
      "rheumatoid arthritis",
      "tofacitinib"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29314645",
  "DateCompleted": {
    "Year": "2018",
    "Month": "08",
    "Day": "27"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2018",
        "Month": "01",
        "Day": "04"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1111/1756-185X.13244"
    ],
    "Journal": {
      "ISSN": "1756-185X",
      "JournalIssue": {
        "Volume": "21",
        "Issue": "2",
        "PubDate": {
          "Year": "2018",
          "Month": "Feb"
        }
      },
      "Title": "International journal of rheumatic diseases",
      "ISOAbbreviation": "Int J Rheum Dis"
    },
    "ArticleTitle": "Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.",
    "Pagination": {
      "StartPage": "402",
      "EndPage": "414",
      "MedlinePgn": "402-414"
    },
    "Abstract": {
      "AbstractText": [
        "Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease-modifying anti rheumatic drugs (csDMARDs) on patient-reported outcomes in Chinese patients with RA and inadequate response to DMARDs.",
        "This analysis of data from the Phase 3 study ORAL Sync included Chinese patients randomized 4 : 4 : 1 : 1 to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo\u2192tofacitinib 5 mg twice daily, or placebo\u2192tofacitinib 10 mg twice daily, with csDMARDs. Placebo non-responders switched to tofacitinib at 3 months; the remaining placebo patients switched at 6 months. Least squares mean changes from baseline were reported for Health Assessment Questionnaire-Disability Index (HAQ-DI), patient assessment of arthritis pain (Pain), patient global assessment of disease activity (PtGA), physician global assessment of disease activity (PGA), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores, Short Form 36 (SF-36), and Work Limitations Questionnaire (WLQ), using a mixed-effects model for repeated measures.",
        "Overall, 216 patients were included (tofacitinib 5 mg twice daily, n = 86; tofacitinib 10 mg twice daily, n = 86; placebo\u2192tofacitinib 5 mg twice daily, n = 22; placebo\u2192tofacitinib 10 mg twice daily, n = 22). At month 3, tofacitinib elicited significant improvements in HAQ-DI, Pain, PtGA, PGA and SF-36 Physical Component Summary scores. Improvements were generally maintained through 12 months.",
        "Tofacitinib 5 and 10 mg twice daily + csDMARDs resulted in improvements in health-related quality of life, physical function and Pain through 12 months in Chinese patients with RA."
      ],
      "CopyrightInformation": "\u00a9 2018 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Peking University People's Hospital, Beijing, China."
          }
        ],
        "LastName": "Li",
        "ForeName": "Zhanguo",
        "Initials": "Z"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Peking University People's Hospital, Beijing, China."
          }
        ],
        "LastName": "An",
        "ForeName": "Yuan",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Qingdao Municipal Hospital, Qingdao, China."
          }
        ],
        "LastName": "Su",
        "ForeName": "Houheng",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Anhui Provincial Hospital, Hefei, Anhui, China."
          }
        ],
        "LastName": "Li",
        "ForeName": "Xiangpei",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "First Affiliated Hospital of Anhui Medical University, Hefei, China."
          }
        ],
        "LastName": "Xu",
        "ForeName": "Jianhua",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Beijing Chaoyang Hospital, Chaoyang District, Beijing, China."
          }
        ],
        "LastName": "Zheng",
        "ForeName": "Yi",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pfizer Inc, Beijing, China."
          }
        ],
        "LastName": "Li",
        "ForeName": "Guiye",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pfizer Inc, New York, New York, USA."
          }
        ],
        "LastName": "Kwok",
        "ForeName": "Kenneth",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pfizer Inc, Groton, Connecticut, USA."
          }
        ],
        "LastName": "Wang",
        "ForeName": "Lisy",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pfizer Inc, Beijing, China."
          }
        ],
        "LastName": "Wu",
        "ForeName": "Qizhe",
        "Initials": "Q"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial, Phase III",
      "Comparative Study",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Int J Rheum Dis",
    "NlmUniqueID": "101474930",
    "ISSNLinking": "1756-1841"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antirheumatic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Piperidines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Protein Kinase Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrimidines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyrroles"
    },
    {
      "RegistryNumber": "87LA6FU830",
      "NameOfSubstance": "tofacitinib"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Antirheumatic Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "physiopathology",
        "psychology"
      ],
      "DescriptorName": "Arthritis, Rheumatoid"
    },
    {
      "QualifierName": [],
      "DescriptorName": "China"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disability Evaluation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Administration Schedule"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Substitution"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Health Status"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pain Measurement"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Patient Reported Outcome Measures"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Piperidines"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Protein Kinase Inhibitors"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Pyrimidines"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects"
      ],
      "DescriptorName": "Pyrroles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Quality of Life"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Recovery of Function"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Young Adult"
    }
  ]
}